title: Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
authors.forename: Kalman
authors.initials: K
authors.lastname: Filanovsky
authors.forename: Lev
authors.initials: L
authors.lastname: Shvidel
authors.forename: Mordechai
authors.initials: M
authors.lastname: Shtalrid
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D000079982:Gemtuzumab; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000079982:Gemtuzumab; D008942:Mitoxantrone